Study of the in vitro activity of amoxicillin/clavulanic acid and other ß-lactam antibiotics against escherichia coli isolated from urine specimens

Acta Clinica Belgica

Volumn 56, Issue 1, 2001, Pages 32-37

  Vanhoof, R ^a   Carpentier, M ^a   Delannoy, P ^a   Fagnart, O ^a   Lontie, M ^a   Mans, I ^a   Nyssen, H J ^a   Van Nimmen, L ^a  

^a PASTEUR INSTITUTE OF BRUSSELS   (Belgium)

Author keywords

Antimicrobial susceptibility; Escherichia coli; Urine specimens

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFUROXIME; CEFUROXIME AXETIL; PIPERACILLIN PLUS TAZOBACTAM; TIMENTIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG POTENCY; DRUG SENSITIVITY; ESCHERICHIA COLI; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; URINALYSIS;

EID: 0035082506     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2001.006     Document Type: Article

References (18)

1. Resistance to amoxicillin/clavulanate in Escherichia coli
2. Resistance to amoxicillin/clavulanate in Escherichia coli
3. Incidence of multi-resistance in Gram-negative bacterial isolates from intensive care units in Belgium: A surveillance study
4. Y-a-t-il en Belgique un accroissement de résistance d'Escherichia coli consideré comme bactérie de référence vis-à-vis de l'association amoxicilline/acide clavulanique
5. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard
6. Performance standards for antimicrobial susceptibility testing; Tenth informational supplement
7. Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli
8. In vitro synergistic properties of clavulanic acid with ampicillin, amoxicillin and ticarcillin
9. Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA- 1 ß-lactamase conferring resistance to ß-lactamase inhibitors
10. Analysis of ß-lactamases produced by cephalothin-susceptible Escherichia coli clinical isolates resistant to co-amoxiclav and ticarcillin-clavulanic acid
11. Characterization of a new TEM type ß-lactamase resistant to clavulanate, sulbactam and tazobactam in a clinical isolates of Escherichia coli
12. ß-Lactam resistance in clinical isolates of Escherichia coli caused by elevated production of the ampC-mediated chromosomal ß-lactamase
13. Resistance to beta lactam/clavulanate
14. Amoxycillin/clavulanate resistance as related to ß-lactamase content in Escherichia coli strains from community-acquired urinary tract infections in Greece
15. Hospital outbreak of Klebsiella pneumoniae resistant to broad-spectrum cephalosporins and ß-lactam-ß-lactamase inhibitor combinations by hyperproduction of SHV-5 ß-lactamase
16. ampR gene mutations that greatly increase class C ß-lactamase activity in Enterobacter cloacae
17. Inactivation of the ampD gene in Pseudomonas aeruginosa leads to moderate basal level and hyperinducible AmpC ß-lactamase expression
18. Factors determining resistance to ß-lactams combined with ß-lactamase inhibitors in Escherichia coli